Procedural steps taken after granting the Marketing Authorisation 
For procedures finalised after 1 September 2004 please refer to module 8B 
Scope 
Application 
number 
Type of 
modification1 
II/01 
I/02 
I/03 
II/0004 
II/05 
II/06 
I/07 
I/08 
I/09 
I/10 
X/11 
II/12 
II 
I 
I 
II 
II 
II 
I 
I 
I 
I/II 
X 
II 
Additional presentation (Flex Pen) 
Change in test procedure of the active 
substance and the medicinal product 
Withdrawal of 2 presentations (vials) 
with the EU numbers 
EU/1/00/142/001-002 
Extension of shelf-life as foreseen at 
the time of authorisation 
Quality changes, additional facility for 
purification of Insulin Aspart  
Optimisation of the manufacturing 
process 
Change for the deletion of the bio 
identity test 
Minor change of the manufacturing 
process of the active substance 
Withdrawal of 2 presentations with the 
EU numbers EU/1/00/142/003 and 
EU/1/00/142/003/006 
Additional site of manufacture and 
additional manufacturer/site 
responsible for batch release of the 
FlexPen finished product (Chartres, 
France). 
Increase of shelf life of NovoMix 30 
FlexPen finished product from 18 to 
24 months 
Minor changes in manufacture of the 
medicinal product 
Qualitative change to the active 
substance(s) 
Revision of the SPC and PL to 
standardise the product information 
text for all Novo Nordisk A/S insulin 
products, and to reflect in the PL the 
results of the readability tests  
Update of sections 4.4 and 4.8 of SPC 
and PL 
Notification/ 
Opinion 
issued on2 
19.10.00 
15.09.00 
Commission 
Decision 
Issued/amended 
on 
29.01.01 
- 
29.01.01 
30.10.00 
22.01.01 
20.09.01 
17.01.02 
21.02.02 
21.02.02 
- 
- 
- 
- 
08.11.02 
16.07.2003 
22.08.03 
08.08.2003 
08.10.03 
25.09.03 
- 
03.06.04 
24.08.04 
26.02.04 
15.04.04 
II/13 
II 
26.02.04 
15.04.04 
1  In  accordance  with  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995,  as  amended,  and  for  variations  after  
1  October  2003  in  accordance  with  Commission  Regulation  (EC)  No  1085/2003:  I  refers  to  a  minor  variation  (Type  I 
variation); II refers to a major variation (Type II variation); I/II refers to a minor variation following the procedure set out in 
Article 6, 7 and 8 of the Regulation; X refers to an Annex II application. 
T  refers  to  a  transfer  of  a  Marketing  Authorisation  in  accordance  with  Commission  Regulation  (EC)  No  2141/96  of  
7 November 1996.  
N refers to a notification in accordance with Article 61(3) of Council Directive 2001/83/EC. 
2  For  Notifications  and  Type  I  variations,  the  date  of  entry  into  force  of  the  change  is  the  EMEA  Notification  date.  The 
Commission Decision will be amended accordingly. 
1/2 
EMEA 2004 
 
 
 
 
 
 
 
 
 
 
 
 
                                                      
 
Update of or change(s) to the 
pharmaceutical documentation 
Update of section 4.2 and 5.1 of the 
SPC and PL to specify the use of 
NovoMix 30 in combination with 
metformin in patients with type 2 
Diabetes mellitus that are 
insufficiently controlled on metformin 
alone. 
Update of or change(s) to the 
pharmaceutical documentation 
Change in the specification of 
immediate packaging - tightening of 
specification limits 
II/14 
II/15 
II/16 
I/17 
II 
II 
II 
Ib 
24.03.04 
22.04.04 
07.07.04 
22.04.04 
22.06.04 
- 
- 
2/2 
EMEA 2004 
 
 
 
 
 
 
 
 
 
 
 
